Nuvation Bio Inc. completed a $250 million public offering of 0.75% Convertible Senior Notes due 2032 on June 30, 2026, with an initial conversion price of approximately $7.84 per share. The company used net proceeds to pay $14.9 million for capped call transactions and to fully repay a $58.5 million loan under a Credit Agreement dated March 3, 2025. The remaining proceeds will be used for general corporate purposes. Nuvation Bio is a biotechnology company that develops therapies for cancer.